Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for SHR-2173, an investigational biologic, in patients with IgA nephropathy.
Developed in-house, SHR-2173 is designed to target abnormally activated immune cells, exerting anti-inflammatory and immune suppressive effects. It has the potential to reduce autoantibody levels and improve disease activity in patients with IgA nephropathy, offering a new treatment option for this condition. To date, no similar product has entered clinical development or been approved for marketing in China. Hengrui has invested a significant amount of RMB 18.93 million in the development of SHR-2173.- Flcube.com
